This invention relates to a pharmaceutical combination comprising (a) a third generation EGFR tyrosine kinase inhibitor and (b) a cyclin D kinase 4/6 (CDK4/6) inhibitor, particularly for use in the treatment of a cancer, particularly a lung cancer. This invention also relates to uses of such a combination for the preparation of a medicament for the treatment of a cancer； methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination； pharmaceutical compositions comprising such combination and commercial packages thereto.
